Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 64.70 Bil Enterprise Value: 57.96 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc Dojolvi US FDA Approval Call Transcript

Jun 30, 2020 / 08:00PM GMT
Release Date Price: MXN1323.83
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Dojolvi U.S. FDA approval call. (Operator Instructions)

I would now like to hand the conference over to your speaker, Ms. Danielle Keatley. Ms. Keatley, the floor is yours.

Danielle Keatley
Ultragenyx Pharmaceutical Inc. - Senior Director of IR & Corporate Communications

Thank you. Good afternoon, and welcome to the Ultragenyx conference call to discuss today's U.S. FDA approval of Dojolvi. We've issued a press release detailing the approval, which you can find on our website at ultragenyx.com. I'm Danielle Keatley, Senior Director of Investor Relations.

Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; and Camille Bedrosian, Chief Medical Officer.

I'd like to remind investors that this call will include forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including, but not limited to, types of statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot